Page last updated: 2024-12-10

1-acetyl-N-propyl-3,4-dihydro-2H-quinoline-6-sulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-acetyl-N-propyl-3,4-dihydro-2H-quinoline-6-sulfonamide is a **synthetic organic compound** that belongs to the class of **quinoline sulfonamides**.

**Structure and Properties:**

* **Quinoline core:** The compound contains a quinoline ring, which is a bicyclic aromatic system.
* **Sulfonamide group:** A sulfonamide group (-SO2NH-) is attached to the sixth position of the quinoline ring.
* **Acetyl group:** An acetyl group (CH3CO-) is attached to the first position of the quinoline ring.
* **N-Propyl group:** A propyl group (CH3CH2CH2-) is attached to the nitrogen atom of the sulfonamide group.

**Research Significance:**

This compound is of interest in research due to its potential **biological activity and pharmacological applications**. While specific research on this exact compound might be limited, the general class of quinoline sulfonamides has been investigated for various therapeutic applications, including:

* **Antimicrobial activity:** Quinoline sulfonamides can exhibit antibacterial and antifungal properties. They can interfere with bacterial growth and metabolism, making them potential candidates for the development of new antibiotics.
* **Anti-inflammatory activity:** Some quinoline sulfonamides have shown anti-inflammatory effects, potentially targeting pathways involved in inflammation. This could lead to the development of drugs for treating inflammatory conditions.
* **Anticancer activity:** Quinoline sulfonamides have been investigated for their potential to inhibit cancer cell growth and proliferation. They might interact with specific targets within cancer cells, leading to cell death or halting cancer progression.
* **Neuroprotective activity:** Some studies have suggested that certain quinoline sulfonamides may have neuroprotective effects, potentially protecting neurons from damage and promoting neurological function.

**Important Considerations:**

* **Specificity and Mechanism:** The specific biological activity and mechanism of action of 1-acetyl-N-propyl-3,4-dihydro-2H-quinoline-6-sulfonamide are unknown.
* **Preclinical research:** Further research is needed to determine the specific properties of this compound, including its potential therapeutic applications, toxicity, and pharmacokinetic characteristics.
* **Clinical trials:** Extensive preclinical and clinical trials are required before any quinoline sulfonamide can be considered for use as a drug.

**In summary:** 1-acetyl-N-propyl-3,4-dihydro-2H-quinoline-6-sulfonamide is a synthetic compound with a potential for pharmacological activity due to its structure and membership in the quinoline sulfonamide class. Further research is needed to explore its specific properties and potential applications.

Cross-References

ID SourceID
PubMed CID3243437
CHEMBL ID1571528
CHEBI ID105332

Synonyms (17)

Synonym
CHEMDIV3_009189
IDI1_027099
1-acetyl-n-propyl-1,2,3,4-tetrahydroquinoline-6-sulfonamide
smr000026847
MLS000045255 ,
CHEBI:105332
AKOS001823995
HMS1499B15
1-acetyl-n-propyl-3,4-dihydro-2h-quinoline-6-sulfonamide
HMS2315H22
CCG-28919
1-ethanoyl-n-propyl-3,4-dihydro-2h-quinoline-6-sulfonamide
bdbm74638
cid_3243437
CHEMBL1571528
Q27183054
Z133628898
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_bHomo sapiens (human)EC50 (µMol)500.00000.918141.9368121.5000AID435026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]